Clinical and demographic characteristics associated with postural instability in patients with schizophrenia / Akihiro Koreki en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 1 (Febrero) . - pp. 16-21 Título : Clinical and demographic characteristics associated with postural instability in patients with schizophrenia Tipo de documento: texto impreso Autores: Akihiro Koreki, Autor ; Kenichi Tsunoda, Autor ; Takefumi Suzuki, Autor Fecha de publicación: 2022 Artículo en la página: pp. 16-21 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Envejecimiento, Antipsicótico, Oscilación postural, Quetiapina, Esquizofrenia, Efecto adverso Resumen: As people with schizophrenia grow older, prevention of falls in this older population has become a public health priority. It is therefore critically important to identify risk factors to effectively prevent falls. For this purpose, the degree of postural sway can serve as a convenient index of risk assessment. Link: ./index.php?lvl=notice_display&id=29403 [artículo] Clinical and demographic characteristics associated with postural instability in patients with schizophrenia [texto impreso] / Akihiro Koreki, Autor ; Kenichi Tsunoda, Autor ; Takefumi Suzuki, Autor . - 2022 . - pp. 16-21. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 1 (Febrero) . - pp. 16-21 Palabras clave: Envejecimiento, Antipsicótico, Oscilación postural, Quetiapina, Esquizofrenia, Efecto adverso Resumen: As people with schizophrenia grow older, prevention of falls in this older population has become a public health priority. It is therefore critically important to identify risk factors to effectively prevent falls. For this purpose, the degree of postural sway can serve as a convenient index of risk assessment. Link: ./index.php?lvl=notice_display&id=29403

Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder / Hiroyuki Uchida en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 6 (Diciembre) . - pp. 545-551 Título : Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder Tipo de documento: texto impreso Autores: Hiroyuki Uchida, Autor ; Hiroyoshi Takeuchi, Autor ; Takefumi Suzuki, Autor Fecha de publicación: 2023 Artículo en la página: pp. 545-551 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Trastorno depresivo mayor, Terapia con medicamentos, Paroxetina, Sulpirida. Resumen: Although serotonin reuptake inhibitors are recommended as first-line agents for major depressive disorder, delayed onset of action is problematic, and faster effective treatment is needed. Sulpiride, a dopamine-mediated agent, has been reported to show faster antidepressant efficacy, and we examined the efficacy of adjunctive sulpiride in combination with paroxetine (PAX), compared with PAX alone, to clarify whether the combined treatment exerts faster effect. Link: ./index.php?lvl=notice_display&id=30879 [artículo] Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder [texto impreso] / Hiroyuki Uchida, Autor ; Hiroyoshi Takeuchi, Autor ; Takefumi Suzuki, Autor . - 2023 . - pp. 545-551. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 6 (Diciembre) . - pp. 545-551 Palabras clave: Antidepresivos, Trastorno depresivo mayor, Terapia con medicamentos, Paroxetina, Sulpirida. Resumen: Although serotonin reuptake inhibitors are recommended as first-line agents for major depressive disorder, delayed onset of action is problematic, and faster effective treatment is needed. Sulpiride, a dopamine-mediated agent, has been reported to show faster antidepressant efficacy, and we examined the efficacy of adjunctive sulpiride in combination with paroxetine (PAX), compared with PAX alone, to clarify whether the combined treatment exerts faster effect. Link: ./index.php?lvl=notice_display&id=30879

Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia / Hiroyoshi Takeuchi en The Journal of Clinical Psychiatry, Año 2014 - Vol.75 - No.11 (Noviembre)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2014 - Vol.75 - No.11 (Noviembre) . - pp. 1209-1214 Título : Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia : findings from an open-label, randomized, controlled study Tipo de documento: texto impreso Autores: Hiroyoshi Takeuchi, Autor ; Takefumi Suzuki, Autor ; Robert R. Bies, Autor Fecha de publicación: 2022 Artículo en la página: pp. 1209-1214 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Benzodiazepinas, Olanzapina, Risperidona, Esquizofrenia. Resumen: While acute-phase antipsychotic response has been attributed to 65%-80% dopamine D₂ receptor blockade, the degree of occupancy for relapse prevention in the maintenance treatment of schizophrenia remains unknown. Link: ./index.php?lvl=notice_display&id=27840 [artículo] Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia : findings from an open-label, randomized, controlled study [texto impreso] / Hiroyoshi Takeuchi, Autor ; Takefumi Suzuki, Autor ; Robert R. Bies, Autor . - 2022 . - pp. 1209-1214. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2014 - Vol.75 - No.11 (Noviembre) . - pp. 1209-1214 Palabras clave: Antipsicóticos, Benzodiazepinas, Olanzapina, Risperidona, Esquizofrenia. Resumen: While acute-phase antipsychotic response has been attributed to 65%-80% dopamine D₂ receptor blockade, the degree of occupancy for relapse prevention in the maintenance treatment of schizophrenia remains unknown. Link: ./index.php?lvl=notice_display&id=27840

Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia / Fumiaki Kumagai en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No.1 (Enero - Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 45-50 Título : Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia : Combined Analysis of 4 RCTs Tipo de documento: texto impreso Autores: Fumiaki Kumagai, Autor ; Takefumi Suzuki, Autor ; Wolfgang Fleischhacker, Autor Fecha de publicación: 2019 Artículo en la página: pp. 45-50 Idioma : Inglés (eng) Palabras clave: Antipsicotico inyectable + placebo, Esquizofrenia. Resumen: Placebo effects remain largely unexplored in clinical trials of long-acting injectable (LAI) antipsychotics for schizophrenia. This study aims to characterize patients showing improvements after placebo injections and to search for criteria for the prediction of subsequent response based on the magnitude of score changes after the first week of treatment. Link: ./index.php?lvl=notice_display&id=20477 [artículo] Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia : Combined Analysis of 4 RCTs [texto impreso] / Fumiaki Kumagai, Autor ; Takefumi Suzuki, Autor ; Wolfgang Fleischhacker, Autor . - 2019 . - pp. 45-50. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 45-50 Palabras clave: Antipsicotico inyectable + placebo, Esquizofrenia. Resumen: Placebo effects remain largely unexplored in clinical trials of long-acting injectable (LAI) antipsychotics for schizophrenia. This study aims to characterize patients showing improvements after placebo injections and to search for criteria for the prediction of subsequent response based on the magnitude of score changes after the first week of treatment. Link: ./index.php?lvl=notice_display&id=20477

Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage / Hitoshi Sakurai en The Journal of Clinical Psychiatry, Año 2016 - Vol.77 - No.10 (Octubre)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2016 - Vol.77 - No.10 (Octubre) . - pp. 1381–1390 Título : Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage : A double-blind randomized controlled trial Tipo de documento: texto impreso Autores: Hitoshi Sakurai, Autor ; Takefumi Suzuki, Autor ; Robert Bies, Autor Fecha de publicación: 2020 Artículo en la página: pp. 1381–1390 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Benzodiacepinas, Resistencia al medicamento, Trastornos psicóticos, Risperidona, Esquizofrenia paranoide, Psicología esquizofrénica. Resumen: While doctors often increase the dose of an antipsychotic when there is insufficient response, there is limited evidence that this intervention is any better than waiting longer on the lower dose. We put the proposition to test. Link: ./index.php?lvl=notice_display&id=21779 [artículo] Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage : A double-blind randomized controlled trial [texto impreso] / Hitoshi Sakurai, Autor ; Takefumi Suzuki, Autor ; Robert Bies, Autor . - 2020 . - pp. 1381–1390. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2016 - Vol.77 - No.10 (Octubre) . - pp. 1381–1390 Palabras clave: Benzodiacepinas, Resistencia al medicamento, Trastornos psicóticos, Risperidona, Esquizofrenia paranoide, Psicología esquizofrénica. Resumen: While doctors often increase the dose of an antipsychotic when there is insufficient response, there is limited evidence that this intervention is any better than waiting longer on the lower dose. We put the proposition to test. Link: ./index.php?lvl=notice_display&id=21779

Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia / Takefumi Suzuki en The British Journal of Psychiatry, Año 2011 - Vol. 199 - No. 4 (Octubre)

Permalink

Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression / Fumihiko Ueno en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.4 (Abril)

Permalink

---

1 (1 - 7 / 7)